Wright Medical Group (NASDAQ: WMGI) and Delcath Systems (OTCMKTS:DCTHD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Valuation and Earnings
This table compares Wright Medical Group and Delcath Systems’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Wright Medical Group||$690.36 million||3.70||-$432.37 million||($2.65)||-9.17|
|Delcath Systems||$1.99 million||0.12||-$17.97 million||($1,554.19)||0.00|
Risk and Volatility
Wright Medical Group has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Delcath Systems has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500.
This table compares Wright Medical Group and Delcath Systems’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Wright Medical Group||-38.40%||-6.27%||-1.71%|
This is a summary of current ratings and recommmendations for Wright Medical Group and Delcath Systems, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Wright Medical Group||0||4||8||0||2.67|
Wright Medical Group presently has a consensus target price of $32.22, suggesting a potential upside of 32.55%. Given Wright Medical Group’s higher possible upside, equities research analysts clearly believe Wright Medical Group is more favorable than Delcath Systems.
Wright Medical Group beats Delcath Systems on 9 of the 10 factors compared between the two stocks.
Wright Medical Group Company Profile
Wright Medical Group, Inc. is a global specialty orthopaedic company. The Company through Wright Medical Technology, Inc. (WMT) and other subsidiaries provides extremity and biologic solutions that enable clinicians to alleviate pain and restore the patients’ lifestyles. The Company operates through three segments: U.S., International and BioMimetic. The Company’s business includes products that are used in foot and ankle repair, upper extremity products and biologics products, which are used to replace damaged or diseased bone, to stimulate bone growth and to provide other biological solutions for surgeons and patients. The Company’s products include extremity hardware, foot and ankle hardware, upper extremity hardware and biologics.
Delcath Systems Company Profile
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
Receive News & Ratings for Wright Medical Group N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wright Medical Group N.V. and related companies with MarketBeat.com's FREE daily email newsletter.